Medications Similar to Mirtazapine

Mechanistically Similar Agents

Trazodone blocks 5-HT2 receptors and has sedating properties, though it works primarily through serotonin reuptake inhibition and α1-adrenergic antagonism, according to the American College of Physicians 1, 2

All second-generation antidepressants, including SSRIs, SNRIs, SSNRIs, and other agents like bupropion, nefazodone, and trazodone, demonstrate equivalent efficacy for treating major depressive disorder, with no clinically significant differences in response rates, remission rates, or quality of life improvements, as recommended by the American Psychiatric Association 1, 3, 4, 5
Specific equivalent options include SSRIs like fluoxetine, paroxetine, sertraline, citalopram, escitalopram, and fluvoxamine, as well as SNRIs like venlafaxine and SSNRIs like duloxetine, according to the American College of Physicians 1, 3

When rapid onset of action is the priority, mirtazapine demonstrates statistically significantly faster onset than citalopram, fluoxetine, paroxetine, or sertraline, with benefits evident within 1-2 weeks, as noted by the American College of Physicians 1, 2, 6
Venlafaxine shows comparable speed of response to mirtazapine, according to the American College of Physicians 1, 2
For depression with comorbid anxiety, all second-generation antidepressants show similar efficacy, with limited evidence suggesting venlafaxine may be superior to fluoxetine, as recommended by the American Psychiatric Association 2, 7
For depression with comorbid insomnia, trazodone is the most commonly used alternative with sedating properties, according to the American Academy of Sleep Medicine 8
Other sedating low-dose antidepressants include doxepin, amitriptyline, and trimipramine, as noted by the American Academy of Sleep Medicine 8
Fluoxetine, nefazodone, paroxetine, and sertraline show similar efficacy for treating depression with insomnia, according to the American College of Physicians 2, 7
For treatment-resistant depression, sustained-release bupropion, sertraline, and extended-release venlafaxine show equivalent efficacy with no differences among them, as recommended by the American Psychiatric Association 1, 5, 9

Mirtazapine's unique advantages include faster onset of antidepressant action, fewer anticholinergic, adrenergic, and serotonergic adverse effects, and beneficial effects on anxiety and sleep disturbance, according to the American College of Physicians 1, 2, 6
Mirtazapine's disadvantages include increased sedation, appetite, and weight gain compared to other second-generation antidepressants, as noted by the American College of Physicians 1

Avoid assuming class-specific superiority, as all second-generation antidepressants achieve similar ultimate response and remission rates by 4-6 weeks, as recommended by the American College of Physicians 1, 3, 4
Consider side effect profiles over efficacy, since efficacy is equivalent, selection should be based on tolerability, comorbid conditions, and patient-specific factors, according to the American College of Physicians 1
Don't overlook the 38% non-response rate, regardless of which second-generation antidepressant is chosen initially, 38% of patients will not respond and 54% will not achieve remission within 6-12 weeks, as noted by the American College of Physicians 1, 5, 9

Mirtazapine should be chosen over an SSRI when rapid onset of antidepressant action is the priority, when the patient has failed or cannot tolerate SSRIs due to sexual dysfunction, or when depression is accompanied by significant insomnia, anxiety, or poor appetite/weight loss 10

Mirtazapine demonstrates statistically significant faster onset of antidepressant effect compared to SSRIs, with clinical benefits evident within 1-2 weeks versus 4-6 weeks for SSRIs 10

Mirtazapine is advantageous when depression presents with poor appetite, weight loss, or cachexia, as it increases appetite and promotes weight gain 10

For menopausal hot flashes, particularly in breast cancer survivors, mirtazapine shows encouraging preliminary efficacy, though tolerance is limited by somnolence and weight gain 11, 12, 13

Despite faster onset, mirtazapine shows no superiority in ultimate response rates, remission rates, or quality of life compared to SSRIs by 6-12 weeks 10
The American College of Physicians recommends selecting second-generation antidepressants based on adverse effect profiles rather than efficacy, as all are equivalent 10

SSRIs are associated with increased risk for nonfatal suicide attempts compared to placebo, while mirtazapine shows no such association 10
This may favor mirtazapine in patients at elevated suicide risk, though direct comparative data are limited 10